From professional translators, enterprises, web pages and freely available translation repositories.
note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease
of medicinal products for the treatment of peripheral arterial occlusive disease
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease:
note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease:
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease (revision)
clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease (revision)
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
philippe cichowlaz, direktør for regionalpolitik og territorial langtidsplanlægning ved cpmr (conference of peripheral maritime regions)
philippe cichowlaz, directeur belast met het regionale beleid en het territoriale verkennend onderzoek van de conferentie van perifere maritieme regio’s in europa (crpm)
Last Update: 2014-02-06
Usage Frequency: 1
Quality:
tenofovirdiphosphat har en intracellulær halveringstid på 10 timer i aktiverede og 50 timer i hvilende mononukleære celler i perifert blod (peripheral blood mononuclear cells, pbmc' er).
tenofovirdifosfaat heeft een intracellulaire halfwaardetijd van 10 uur in geactiveerde en van 50 uur in rustende perifere mononucleaire bloedcellen (pbmc’ s).
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
titel på dokumentet note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti- depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti- bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
titel document note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti-depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti-bacterial medicinal product (cpmp/ewp/558/95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.